{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:35Z","timestamp":1761895895872},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,20]],"date-time":"2014-07-20T00:00:00Z","timestamp":1405814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00277-014-2164-3","type":"journal-article","created":{"date-parts":[[2014,7,19]],"date-time":"2014-07-19T05:23:05Z","timestamp":1405747385000},"page":"97-105","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of lenalidomide in relapse\/refractory multiple myeloma\u2014Real life experience of a tertiary cancer center"],"prefix":"10.1007","volume":"94","author":[{"given":"Cristina","family":"Jo\u00e3o","sequence":"first","affiliation":[]},{"given":"In\u00eas","family":"Coelho","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Esteves","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Lucio","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,7,20]]},"reference":[{"key":"2164_CR1","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1182\/blood-2006-09-043034","volume":"108","author":"S Lonial","year":"2006","unstructured":"Lonial S (2006) When \u201cthe same\u201d is really \u201cdifferent\u201d. Blood 108:3233\u20133234","journal-title":"Blood"},{"key":"2164_CR2","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","volume":"23","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Chen C, Spencer A (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23:2147\u20132152. doi: 10.1038\/leu.2009.147","journal-title":"Leukemia"},{"key":"2164_CR3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516\u20132520. doi: 10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"key":"2164_CR4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach H, Ritchie D, Stewart AK et al (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24:22\u201332. doi: 10.1038\/leu.2009.236","journal-title":"Leukemia"},{"key":"2164_CR5","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy PL et al (2012) Lenalidomide after stem-cell transplantation for multiple myeloma\u2014NEJM. N Engl J Med 366:1770\u20131781. doi: 10.1056\/NEJMoa1114083","journal-title":"N Engl J Med"},{"key":"2164_CR6","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal M et al (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma\u2014NEJM. N Engl J Med 366:1782\u20131791","journal-title":"N Engl J Med"},{"key":"2164_CR7","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A et al (2012) Continuous lenalidomide treatment for newly diagnosed multiple myeloma\u2014NEJM. N Engl J Med 366:1759\u20131769","journal-title":"N Engl J Med"},{"key":"2164_CR8","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4065\/82.10.1179","volume":"82","author":"MQ Lacy","year":"2007","unstructured":"Lacy MQ, Gertz MA, Dispenzieri A et al (2007) Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82:1179\u20131184. doi: 10.4065\/82.10.1179","journal-title":"Mayo Clin Proc"},{"key":"2164_CR9","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3324\/haematol.2009.015917","volume":"95","author":"J-L Harousseau","year":"2010","unstructured":"Harousseau J-L, Dimopoulos MA, Wang M et al (2010) Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 95:1738\u20131744. doi: 10.3324\/haematol.2009.015917","journal-title":"Haematologica"},{"key":"2164_CR10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3816\/CLML.2010.n.120","volume":"11","author":"JF San-Miguel","year":"2011","unstructured":"San-Miguel JF, Dimopoulos MA, Stadtmauer EA et al (2011) Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 11:38\u201343. doi: 10.3816\/CLML.2010.n.120","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2164_CR11","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","volume":"112","author":"M Wang","year":"2008","unstructured":"Wang M, Dimopoulos MA, Chen C et al (2008) Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112:4445\u20134451. doi: 10.1182\/blood-2008-02-141614","journal-title":"Blood"},{"key":"2164_CR12","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau J-L, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473. doi: 10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"2164_CR13","doi-asserted-by":"crossref","unstructured":"PayerlTeam, RDevelopment Core. \u201cR: A language and environment for statistical computing.\u201d R foundation for Statistical Computing (2005).e G (2005) Scholar. 3:45. doi: 10.2307\/302397","DOI":"10.2307\/302397"},{"key":"2164_CR14","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","volume":"118","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Bringhen S, Ludwig H et al (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118:4519\u20134529. doi: 10.1182\/blood-2011-06-358812","journal-title":"Blood"},{"key":"2164_CR15","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2008.402","volume":"23","author":"E Kastritis","year":"2009","unstructured":"Kastritis E, Zervas K, Symeonidis A et al (2009) Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 23:1152\u20131157. doi: 10.1038\/leu.2008.402","journal-title":"Leukemia"},{"key":"2164_CR16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ et al (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26:149\u2013157. doi: 10.1038\/leu.2011.196","journal-title":"Leukemia"},{"key":"2164_CR17","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2009.01257.x","volume":"82","author":"EA Stadtmauer","year":"2009","unstructured":"Stadtmauer EA, Weber DM, Niesvizky R et al (2009) Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 82:426\u2013432. doi: 10.1111\/j.1600-0609.2009.01257.x","journal-title":"Eur J Haematol"},{"key":"2164_CR18","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu YX, Braggio E, Shi C-X et al (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118:4771\u20134779. doi: 10.1182\/blood-2011-05-356063","journal-title":"Blood"},{"key":"2164_CR19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bjh.12338","volume":"161","author":"D Heintel","year":"2013","unstructured":"Heintel D, Rocci A, Ludwig H et al (2013) High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 161:695\u2013700. doi: 10.1111\/bjh.12338","journal-title":"Br J Haematol"},{"key":"2164_CR20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Nat Rev Cancer 12:335\u2013348. doi: 10.1038\/nrc3257","journal-title":"Nat Rev Cancer"},{"key":"2164_CR21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2012.226","volume":"27","author":"F Magrangeas","year":"2013","unstructured":"Magrangeas F, Avet-Loiseau H, Gouraud W et al (2013) Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 27:473\u2013481. doi: 10.1038\/leu.2012.226","journal-title":"Leukemia"},{"key":"2164_CR22","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","volume":"114","author":"J-L Harousseau","year":"2009","unstructured":"Harousseau J-L, Attal M, Avet-Loiseau H (2009) The role of complete response in multiple myeloma. Blood 114:3139\u20133146. doi: 10.1182\/blood-2009-03-201053","journal-title":"Blood"},{"key":"2164_CR23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/leu.2011.3","volume":"25","author":"MA Dimopoulos","year":"2011","unstructured":"Dimopoulos MA, Palumbo A, Attal M et al (2011) Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: Consensus statement. Leukemia 25:749\u2013760. doi: 10.1038\/leu.2011.3","journal-title":"Leukemia"},{"key":"2164_CR24","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","volume":"115","author":"F Gay","year":"2010","unstructured":"Gay F, Hayman SR, Lacy MQ et al (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115:1343\u20131350. doi: 10.1182\/blood-2009-08-239046","journal-title":"Blood"},{"key":"2164_CR25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","volume":"119","author":"GJ Morgan","year":"2012","unstructured":"Morgan GJ, Gregory WM, Davies FE et al (2012) The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119:7\u201315. doi: 10.1182\/blood-2011-06-357038","journal-title":"Blood"},{"key":"2164_CR26","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.leukres.2012.04.001","volume":"36","author":"Y Kagoya","year":"2012","unstructured":"Kagoya Y, Nannya Y, Kurokawa M (2012) Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis. Leuk Res 36:1016\u20131021. doi: 10.1016\/j.leukres.2012.04.001","journal-title":"Leuk Res"},{"key":"2164_CR27","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2011-04-350009","volume":"118","author":"S Madan","year":"2011","unstructured":"Madan S, Lacy MQ, Dispenzieri A et al (2011) Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood 118:1763\u20131765. doi: 10.1182\/blood-2011-04-350009","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2164-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2164-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2164-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:49:53Z","timestamp":1559036993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2164-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,20]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["2164"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2164-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,20]]}}}